

# Steinbjørn Hansen

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/311748/steinbjorn-hansen-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

44  
papers

4,888  
citations

23  
h-index

44  
g-index

44  
ext. papers

5,701  
ext. citations

5.3  
avg, IF

4.86  
L-index

| #  | Paper  | IF   | Citations |
|----|--|------|-----------|
| 44 | Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. <i>Lancet, The</i> , <b>2010</b> , 376, 1147-54  | 4.0  | 2311      |
| 43 | Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, 700-12 | 21.7 | 982       |
| 42 | Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3189-3197   | 2.2  | 168       |
| 41 | Epidemiology of glioma: clinical characteristics, symptoms, and predictors of glioma patients grade I-IV in the the Danish Neuro-Oncology Registry. <i>Journal of Neuro-Oncology</i> , <b>2017</b> , 135, 571-579  | 4.8  | 121       |
| 40 | Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. <i>Annals of Oncology</i> , <b>2013</b> , 24, 2402-8   | 10.3 | 107       |
| 39 | Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. <i>Neuro-Oncology</i> , <b>2010</b> , 12, 508-16   | 1    | 107       |
| 38 | Tumour-associated microglia/macrophages predict poor prognosis in high-grade gliomas and correlate with an aggressive tumour subtype. <i>Neuropathology and Applied Neurobiology</i> , <b>2018</b> , 44, 185-206   | 5.2  | 105       |
| 37 | Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. <i>European Journal of Endocrinology</i> , <b>2009</b> , 161, 631-7   | 6.5  | 92        |
| 36 | Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. <i>British Journal of Cancer</i> , <b>1998</b> , 77, 932-40  | 8.7  | 83        |
| 35 | MiR-21 expression in the tumor cell compartment holds unfavorable prognostic value in gliomas. <i>Journal of Neuro-Oncology</i> , <b>2013</b> , 111, 71-81   | 4.8  | 80        |
| 34 | Low expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in glioblastoma predicts longer patient survival. <i>Journal of Neuro-Oncology</i> , <b>2009</b> , 95, 117-128   | 4.8  | 60        |
| 33 | A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy. <i>Acta Oncologica</i> , <b>2012</b> , 51, 797-804   | 3.2  | 51        |
| 32 | Statin use and survival following glioblastoma multiforme. <i>Cancer Epidemiology</i> , <b>2014</b> , 38, 722-7  | 2.8  | 49        |
| 31 | High levels of c-Met is associated with poor prognosis in glioblastoma. <i>Journal of Neuro-Oncology</i> , <b>2015</b> , 122, 517-27   | 4.8  | 47        |
| 30 | Docetaxel rechallenge after an initial good response in patients with metastatic castration-resistant prostate cancer. <i>BJU International</i> , <b>2015</b> , 115, 744-52  | 5.6  | 40        |
| 29 | Living alone, obesity and smoking: important factors for quality of life after radiotherapy and androgen deprivation therapy for prostate cancer. <i>Acta Oncologica</i> , <b>2012</b> , 51, 722-9   | 3.2  | 40        |
| 28 | Expression and prognostic value of the WEE1 kinase in gliomas. <i>Journal of Neuro-Oncology</i> , <b>2016</b> , 127, 381-9   | 4.8  | 39        |

|    |   |     |    |
|----|---|-----|----|
| 27 | Prognostic value of Musashi-1 in gliomas. <i>Journal of Neuro-Oncology</i> , <b>2013</b> , 115, 453-61  | 4.8 | 36 |
| 26 | Transferrin receptor-1 and ferritin heavy and light chains in astrocytic brain tumors: Expression and prognostic value. <i>PLoS ONE</i> , <b>2017</b> , 12, e0182954  | 3.7 | 36 |
| 25 | The effects of multidisciplinary rehabilitation: RePCa-a randomised study among primary prostate cancer patients. <i>British Journal of Cancer</i> , <b>2013</b> , 109, 3005-13   | 8.7 | 30 |
| 24 | A population-based study of low-grade gliomas and mutated isocitrate dehydrogenase 1 (IDH1). <i>Journal of Neuro-Oncology</i> , <b>2013</b> , 114, 309-17   | 4.8 | 29 |
| 23 | Independent prognostic value of angiogenesis and the level of plasminogen activator inhibitor type 1 in breast cancer patients. <i>British Journal of Cancer</i> , <b>2003</b> , 88, 102-8  | 8.7 | 28 |
| 22 | Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study. <i>Acta Oncologica</i> , <b>2014</b> , 53, 939-44         | 3.2 | 24 |
| 21 | Glioma Cells in the Tumor Periphery Have a Stem Cell Phenotype. <i>PLoS ONE</i> , <b>2016</b> , 11, e0155106  | 3.7 | 21 |
| 20 | Treatment and survival of glioblastoma patients in Denmark: The Danish Neuro-Oncology Registry 2009-2014. <i>Journal of Neuro-Oncology</i> , <b>2018</b> , 139, 479-489   | 4.8 | 21 |
| 19 | Prognostic value of O-6-methylguanine-DNA methyltransferase (MGMT) protein expression in glioblastoma excluding nontumour cells from the analysis. <i>Neuropathology and Applied Neurobiology</i> , <b>2018</b> , 44, 172-184                           | 5.2 | 20 |
| 18 | Embracing life after prostate cancer. A male perspective on treatment and rehabilitation. <i>European Journal of Cancer Care</i> , <b>2013</b> , 22, 549-58   | 2.4 | 19 |
| 17 | Salvage radiation therapy following radical prostatectomy. A national Danish study. <i>Acta Oncologica</i> , <b>2016</b> , 55, 598-603  | 3.2 | 15 |
| 16 | Precision and accuracy of a noninvasive inert gas washin method for determination of cardiac output in men. <i>Journal of Applied Physiology</i> , <b>1994</b> , 76, 1560-5   | 3.7 | 13 |
| 15 | The Danish Neuro-Oncology Registry: establishment, completeness and validity. <i>BMC Research Notes</i> , <b>2016</b> , 9, 425  | 2.3 | 11 |
| 14 | Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial. <i>Acta Oncologica</i> , <b>2017</b> , 56, 1776-1785           | 3.2 | 11 |
| 13 | Repeatability of the acetylene rebreathing method in measuring cardiac output: influence of acetylene concentration. <i>Acta Anaesthesiologica Scandinavica</i> , <b>1990</b> , 34, 354-7   | 1.9 | 11 |
| 12 | Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan. <i>Acta Oncologica</i> , <b>2016</b> , 55, 418-22   | 3.2 | 10 |
| 11 | Male coping through a long-term cancer trajectory. Secondary outcomes from a RTC examining the effect of a multidisciplinary rehabilitation program (RePCa) among radiated men with prostate cancer. <i>Acta Oncologica</i> , <b>2017</b> , 56, 254-261 | 3.2 | 9  |
| 10 | Phase I/II study on docetaxel, gemcitabine and prednisone in castrate refractory metastatic prostate cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2010</b> , 66, 295-301  | 3.5 | 9  |

|   |  |     |   |
|---|--|-----|---|
| 9 | Estimates of the sources of variation (variance components) of bioelectric impedance and anthropometric measurements in an epidemiological case-control study of breast cancer. <i>European Journal of Clinical Nutrition</i> , <b>1997</b> , 51, 764-70 | 5.2 | 9 |
| 8 | Expression and prognostic value of JAM-A in gliomas. <i>Journal of Neuro-Oncology</i> , <b>2017</b> , 135, 107-117   | 4.8 | 8 |
| 7 | Novel approaches for quantifying protein biomarkers in gliomas: benefits and pitfalls. <i>CNS Oncology</i> , <b>2014</b> , 3, 287-98   | 4   | 8 |
| 6 | APNG as a prognostic marker in patients with glioblastoma. <i>PLoS ONE</i> , <b>2017</b> , 12, e0178693  | 3.7 | 8 |
| 5 | The Danish Neuro-Oncology Registry. <i>Clinical Epidemiology</i> , <b>2016</b> , 8, 629-632  | 5.9 | 6 |
| 4 | The non-invasive acetylene rebreathing method for estimation of cardiac output: influence of breath-by-breath variation. <i>Clinical Physiology</i> , <b>1997</b> , 17, 193-202  |     | 5 |
| 3 | Late urinary morbidity and quality of life after radical prostatectomy and salvage radiotherapy for prostate cancer. <i>Scandinavian Journal of Urology</i> , <b>2017</b> , 51, 457-463  | 1.6 | 4 |
| 2 | The Danish Prostate Cancer Database. <i>Clinical Epidemiology</i> , <b>2016</b> , 8, 649-653   | 5.9 | 4 |
| 1 | Prognostic role of Ki-67 in glioblastomas excluding contribution from non-neoplastic cells. <i>Scientific Reports</i> , <b>2021</b> , 11, 17918  | 4.9 | 1 |